MDVX - H-CYTE, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4025
+0.0175 (+4.55%)
At close: 1:56PM EDT
Stock chart is not supported by your current browser
Previous Close0.3850
Open0.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3900 - 0.4025
52 Week Range0.2110 - 0.6500
Volume8,750
Avg. Volume43,682
Market Cap39.802M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.75
Trade prices are not sourced from all markets
  • GlobeNewswire20 days ago

    H-CYTE Bolsters Board of Directors With Appointment of Dr. Andre Terzic to Board of Directors

    H-CYTE Inc. (OTCQB:HCYT) (“H-CYTE” or the “Company”), the owner and operator of innovative medical technology products and services including Lung Health Institute, today announced it has appointed Andre Terzic, M.D., Ph.D., to its Board of Directors. Dr. Andre Terzic is the Michael & Mary Sue Shannon Director, Mayo Clinic Center for Regenerative Medicine, Marriott Family Professor of Cardiovascular Diseases Research and Professor of Medicine and Pharmacology.

  • GlobeNewswirelast month

    H-CYTE Comments on Recent Promotional Activity

    H-CYTE, INC. (OTCQB:HCYT), wishes to make, at the request of the OTC Markets Group Inc., the following release regarding certain market activity surrounding the Company's common shares. On July 15, 2019, the Company was notified by the OTC Markets about certain promotional activities in relation to the Common Shares, including certain promotional newsletter emails dated July 12, 2019 and July 15, 2019, distributed by Penny Stock Prophet, Secret Stock Promoter and OTC Tip Reporter. At no time has the Company entered into a contract, unwritten agreement or understanding with the aforementioned above entities.

  • GlobeNewswirelast month

    Medovex Corporation Announces Name Change to H-CYTE and New Ticker Symbol

    Medovex Corp. (MDVX), today announced that FINRA has approved the effectiveness of a change in the company’s name from “Medovex Corp.” to “H-CYTE, Inc.” as well as a change in the Company’s trading symbol from “MDVX” to the new trading symbol “HCYT”. In addition, a new CUSIP number has been assigned to the Company’s common stock. The new CUSIP number for the Company’s common stock is 404124109.

  • GlobeNewswire2 months ago

    Medovex Corporation Updates Name Change and Full Rebranding to H-CYTE

    The announcement underscores the Company's broader commitment focusing on delivering regenerative anti-inflammatory solutions to treat the unmet needs of patients, as well as bringing new health care solutions to patients domestically and internationally with a focus on improving quality of life, especially for those with chronic diseases. In addition to the name and anticipated symbol change, the Company will launch a new corporate website and social channels to provide educational resources for patients. The name change and an accompanying ticker symbol remain subject to the approval of the Financial Industry Regulatory Authority (FINRA).

  • GlobeNewswire2 months ago

    Medovex’s Transition to H-CYTE Underscores Biotechnology Focus

    Medovex Corp. (OTCQB:Symbol MDVX) ("Medovex" or the "Company"), is transitioning to its new name H-CYTE Inc. (“H-CYTE”) to underscore its focus of delivering regenerative anti-inflammatory solutions to treat the unmet needs of patients. Within its portfolio, the Company announced today H-CYTE will enhance its existing cytotherapy product line, developing a disruptive technology for chronic obstructive pulmonary disease (“COPD”), the fourth leading cause of death in the U.S. To accelerate this vision, a 10-year exclusive and extendable supply agreement with Rion LLC (“Rion”) has been executed that enables H-CYTE to develop proprietary biologics.

  • GlobeNewswire4 months ago

    Medovex Corporation Announces Recent Management Appointments

    Medovex Corporation (MDVX) (“Medovex” or the “Company”), the owner and operator of innovative medical technology products and services including Lung Health Institute and the DenerveX® System, today announced a series of new management appointments bolstering its management team following the recent appointment of Bill Horne as Chief Executive Officer. "I’m pleased to welcome Jeremy, Ann, Briley and Gary to our management team.

  • GlobeNewswire4 months ago

    Medovex Corporation Closes Financing for a Total $7.2M Under Existing Securities Purchase Agreement

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today announced that on April 1, 2019, the Company entered into a securities purchase agreement with five purchasers pursuant to which the five purchasers invested in the Company an aggregate amount of $575,000. Previously on March 11, 2019, the Company entered into a securities purchase agreement with eight purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $1,250,000.

  • GlobeNewswire5 months ago

    Medovex Corporation Receives an Additional $1.25 Million Under Existing Securities Purchase Agreement

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today announced that on March 11, 2019, the Company entered into a securities purchase agreement with eight purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $1,250,000. The Company last announced on January 18, 2019, it had entered into a securities purchase agreement with six purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $2,900,000.

  • GlobeNewswire6 months ago

    Medovex Corporation Announces Name Change and Full Rebranding to Blue Zone Health

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today announced it is now Blue Zone Health. The announcement signals the company's broader commitment to bringing new health care solutions to patients domestically and internationally with a focus on improving quality of life, especially for those with chronic diseases. Blue Zone Health adopts its name from the “Blue Zones,” research spearheaded by Dan Buettner, showing the key to longevity lies in a holistic, daily approach to wellness.

  • GlobeNewswire7 months ago

    Medovex Corporation Receives an Additional $2.9 Million Under Existing Securities Purchase Agreement

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today announced that on January 18, 2019, the Company entered into a securities purchase agreement with six purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $2,900,000. Medovex previously announced that on January 8, 2019, the Company entered into a securities purchase agreement with four purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $2,000,000, with $1,800,000 in cash and $200,000 by cancellation of debt.

  • GlobeNewswire7 months ago

    Medovex Corporation Enters into Securities Purchase Agreement

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today announced that on January 8, 2019, the Company entered into a securities purchase agreement with four purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $2,000,000, with $1,800,000 in cash and $200,000 by cancellation of debt. The agreement includes the customary representations and warranties from the Company and purchasers.

  • GlobeNewswire7 months ago

    Medovex Corporation Announces New Board Appointments

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today named Michael Yurkowsky, founder of YP Holdings, and Raymond Monteleone, formerly of Arthur Young (now EY), to its board of directors, effective immediately.

  • GlobeNewswire7 months ago

    Medovex Corporation Closes Acquisition of Pulmonary Biomedical Services and Patient Delivery Platform of Regenerative Medicine Solutions, LLC

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today announced that it has closed the acquisition of substantially all of the assets of Regenerative Medicine Solutions, LLC (“RMS”). RMS is a Tampa, Florida-based pulmonary biomedical services and patient delivery platform that manages and operates Lung Health Institute, a leader in regenerative medicine specializing in cellular therapies to treat chronic obstructive pulmonary disease (COPD) and other chronic lung diseases.